AnalystsRichard Law
Richard Law's Stock Forecasts

Sectors:
Industries:
Analyst Ranking
Top 27%
#1335 out of 4929 analysts
Average Return
+3.55%
Win Rate
41%13 out of 32
Risk vs Reward
Poor
Good

Richard Law's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Olema Pharmaceuticals IncOLMA
+234.19%$3.89$13.00
2023-03-10 -
2024-03-08
Buy
Olema Pharmaceuticals IncOLMA
+204.17%$4.56$13.87
2023-02-22 -
2024-02-21
Buy
Arvinas IncARVN
+46.97%$31.98$47.00
2023-02-24 -
2024-02-23
Buy
Mineralys Therapeutics IncMLYS
+42.55%$10.20$14.54
2025-02-13 -
2025-07-03
Strong Buy
Arvinas IncARVN
+39.16%$24.67$34.33
2023-05-08 -
2024-05-07
Buy

Richard Law Analyst Color

Get additional color on Richard Law's coverage of popular stocks

Richard Law's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Olema Pharmaceuticals IncOLMA
5Strong Buy$18.00+293.87%Maintains
2 months ago
Silence Therapeutics PLCSLN
3Strong Sell$3.00-45.65%Maintains
2 months ago
Rocket Pharmaceuticals IncRCKT
3Hold$13.00+348.28%Maintains
2 months ago
Celldex Therapeutics IncCLDX
3Hold$31.00+40.91%Maintains
2 months ago
Viridian Therapeutics IncVRDN
3Strong Buy$27.00+72.30%Maintains
2 months ago
Viking Therapeutics IncVKTX
1Hold$30.00+6.42%Initiates Coverage On
3 months ago
Moonlake ImmunotherapeuticsMLTX
3Strong Buy$73.00+49.31%Maintains
4 months ago
Mineralys Therapeutics IncMLYS
6Strong Buy$24.00+65.06%Maintains
5 months ago
Merus NvMRUS
1Strong Buy$73.00+35.64%Initiates Coverage On
7 months ago
Monte Rosa Therapeutics IncGLUE
4Hold$11.00N/AReiterates
2 years ago
Verve Therapeutics IncVERV
2Hold$31.00N/AReiterates
2 years ago
Beam Therapeutics IncBEAM
3Hold$47.00N/AMaintains
2 years ago
Crispr Therapeutics AgCRSP
6Hold$63.00N/AMaintains
2 years ago
Kymera Therapeutics IncKYMR
8Hold$37.00N/AMaintains
2 years ago
Intellia Therapeutics IncNTLA
5Buy$76.00N/AReiterates
2 years ago
Q32 Bio IncQTTB
4Hold$36.00N/AReiterates
2 years ago
Editas Medicine IncEDIT
3Hold$14.00N/AMaintains
2 years ago
Arvinas IncARVN
4Buy$61.00N/AReiterates
2 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.